← Leaderboards
Theodore W. Randolph
University Of Colorado At Boulder
$11,330,861
Attributed
$14,222,032
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,222,032 · 7
By mechanism
R01$10,230,767 · 2
T32$2,734,471 · 1
R21$524,033 · 1
R43$510,380 · 2
R41$222,381 · 1
Top collaborators
- Christopher Peter Calderon3 shared
- Andrew P Goodwin3 shared
- Claudia Flynn1 shared
- Darrell J Irvine1 shared
- William R Schief1 shared
Most similar at University Of Colorado At Boulder
Same institution · by research overlap
- Steven M George$2,982,022
- Alan W Weimer$1,711,772
- Robert A Hall$302,326
- Bart J Van Zeghbroeck$508,741
- Richard D Noble$1,650,942
Others in their field
Top investigators on “Biotechnology”
- David Heimbrook · Leidos Biomedical Research, Inc.$140,255,767
- Larry Arthur$82,860,406
- Jaap Goudsmit · Beth Israel Deaconess Medical Center$53,211,858
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$51,699,453
- Richard A Gibbs · Baylor College Of Medicine$51,685,612
- Garret A Fitzgerald · University Of Pennsylvania$50,415,853
Research focus
BiotechnologyPharmacologic SubstanceDesignImmune ResponseTherapeutic ProteinProteinsInsightComplementModificationSurfacePolymersKineticsParticleMalignant NeoplasmsLiquid SubstanceSafetyComputer SimulationHuman DiseaseProtein AggregationHemophilia APharmaceutical PreparationsIntermolecular InteractionImageMolecular
Grant awards (33)
Design of single-shot sequential immunization regimens for HIV using atomic layer deposition technology.$3,017,032
R01 · FY2025 · AI
High-Throughput, Label-Free, Unsupervised Image Analysis of CAR-T Cell Data$285,577
R43 · FY2024 · GM
A New Tool to Rapidly Diagnose Sepsis using Flow Imaging Microscopy and Machine Learning$224,803
R43 · FY2020 · EB
Effect of Container Surface Structure on Cavitation-Induced Protein Particulate Formation$173,920
R21 · FY2019 · EB
Quantitative Biotherapeutic Particle Characterization via Deep Neural Networks$222,381
R41 · FY2018 · GM
Effect of Container Surface Structure on Cavitation-Induced Protein Particulate Formation$212,961
R21 · FY2018 · EB
Effect of Container Surface Structure on Cavitation-Induced Protein Particulate Formation$137,152
R21 · FY2018 · EB
Biotechnology Research Partnerships Renewal: Aggregation of Therapeutic Proteins$834,437
R01 · FY2017 · EB · contact PI
Biotechnology Research Partnerships Renewal: Aggregation of Therapeutic Proteins$843,392
R01 · FY2016 · EB · contact PI
Biotechnology Research Partnerships Renewal: Aggregation of Therapeutic Proteins$834,791
R01 · FY2015 · EB · contact PI
Leadership Training in Pharmaceutical Biotechnology$72,507
T32 · FY2015 · GM · contact PI
Biotechnology Research Partnerships Renewal: Aggregation of Therapeutic Proteins$826,561
R01 · FY2014 · EB · contact PI
Leadership Training in Pharmaceutical Biotechnology$219,846
T32 · FY2014 · GM · contact PI
Biotechnology Research Partnerships Renewal: Aggregation of Therapeutic Proteins$899,050
R01 · FY2013 · EB · contact PI
Leadership Training in Pharmaceutical Biotechnology$216,969
T32 · FY2013 · GM · contact PI
Leadership Training in Pharmaceutical Biotechnology$216,969
T32 · FY2012 · GM · contact PI
Leadership Training in Pharmaceutical Biotechnology$214,168
T32 · FY2011 · GM · contact PI
Aggregation of Protein Therapeutics: Mechanisms, Stability, and Interdiction$573,791
R01 · FY2010 · EB · contact PI
Leadership Training in Pharmaceutical Biotechnology$96,736
T32 · FY2010 · GM · contact PI
Aggregation of Protein Therapeutics: Mechanisms, Stability, and Interdiction$563,593
R01 · FY2009 · EB · contact PI
Leadership Training in Pharmaceutical Biotechnology$222,588
T32 · FY2009 · GM · contact PI
Aggregation of Protein Therapeutics: Mechanisms, Stability, and Interdiction$126,713
R01 · FY2009 · EB · contact PI
Aggregation of Protein Therapeutics: Mechanisms, Stability, and Interdiction$548,076
R01 · FY2008 · EB · contact PI
Leadership Training in Pharmaceutical Biotechnology$221,267
T32 · FY2008 · GM · contact PI
Aggregation of Protein Therapeutics: Mechanisms, Stability, and Interdiction$590,706
R01 · FY2007 · EB · contact PI
Leadership Training in Pharmaceutical Biotechnology$221,266
T32 · FY2007 · GM · contact PI
Aggregation of Protein Therapeutics: Mechanisms, Stability, and Interdiction$572,625
R01 · FY2006 · EB · contact PI
Leadership Training in Pharmaceutical Biotechnology$75,061
T32 · FY2006 · GM · contact PI
LEADERSHIP TRAINING IN PHARMACEUTICAL BIOTECHNOLOGY$201,647
T32 · FY2005 · GM
LEADERSHIP TRAINING IN PHARMACEUTICAL BIOTECHNOLOGY$201,647
T32 · FY2004 · GM
LEADERSHIP TRAINING IN PHARMACEUTICAL BIOTECHNOLOGY$196,437
T32 · FY2003 · GM
LEADERSHIP TRAINING IN PHARMACEUTICAL BIOTECHNOLOGY$184,695
T32 · FY2002 · GM
LEADERSHIP TRAINING IN PHARMACEUTICAL BIOTECHNOLOGY$172,668
T32 · FY2001 · GM